Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 5, 2022
Discovery & Translation

Intima’s public neoantigen discovery platform; plus MS autoantigens and more

BioCentury’s roundup of translational news
BioCentury | Jul 1, 2021
Distillery Therapeutics

Sensitizing TNBC to apoptosis-promoting BH3 mimetics with NamPRT inhibitors

DISEASE CATEGORY: Cancer
INDICATION: Breast cancer Inhibiting NamPRT, a nicotinamide adenine dinucleotide (NAD+) biosynthesis enzyme, could sensitize triple-negative breast cancer (TNBC) to BH3
BioCentury | Dec 15, 2017
Preclinical News

A new role for Bcl-XL in fibrosis

BioCentury | Aug 14, 2014
Distillery Techniques

Technology: Assays & screens

BioCentury | Jun 24, 2013
Clinical News

PraediCare Dx: Data

BioCentury | Feb 28, 2013
Distillery Therapeutics

Indication: Cancer

BioCentury | Nov 15, 2012
Distillery Techniques

Technology: Markers

BioCentury | Apr 5, 2012
Distillery Techniques

Technology: Markers

BioCentury | Dec 15, 2011
Tools & Techniques

Priming chemo prediction

Items per page:
1 - 10 of 12